Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone908-809-1300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$263.70 million
Profitability
Miscellaneous
Employees466
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions
What is Osmotica Pharmaceuticals' stock symbol?
Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."
How were Osmotica Pharmaceuticals' earnings last quarter?
Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.08. The company had revenue of $57.13 million for the quarter, compared to analysts' expectations of $53.58 million. View Osmotica Pharmaceuticals' Earnings History.
When is Osmotica Pharmaceuticals' next earnings date?
What price target have analysts set for OSMT?
4 brokerages have issued 1 year price targets for Osmotica Pharmaceuticals' shares. Their forecasts range from $14.00 to $17.00. On average, they expect Osmotica Pharmaceuticals' stock price to reach $15.50 in the next year. This suggests a possible upside of 496.2% from the stock's current price. View Analyst Price Targets for Osmotica Pharmaceuticals.
What is the consensus analysts' recommendation for Osmotica Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Osmotica Pharmaceuticals.
Has Osmotica Pharmaceuticals been receiving favorable news coverage?
News coverage about OSMT stock has been trending negative on Friday, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Osmotica Pharmaceuticals earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Osmotica Pharmaceuticals' key competitors?
Some companies that are related to Osmotica Pharmaceuticals include CytomX Therapeutics (CTMX), Flexion Therapeutics (FLXN), Corbus Pharmaceuticals (CRBP), MediciNova (MNOV), Evolus (EOLS), Milestone Pharmaceuticals (MIST), NuCana (NCNA), Corium International (CORI), INDIVIOR PLC/S (INVVY), ProQR Therapeutics (PRQR), BioSpecifics Technologies (BSTC), NextCure (NXTC), Arcus Biosciences (RCUS), Albireo Pharma (ALBO) and Dynavax Technologies (DVAX).
What other stocks do shareholders of Osmotica Pharmaceuticals own?
Who are Osmotica Pharmaceuticals' key executives?
Osmotica Pharmaceuticals' management team includes the folowing people:
- Mr. Brian A. Markison, Chairman, Pres & CEO (Age 60)
- Mr. Andrew J. Einhorn, Chief Financial Officer (Age 59)
- Dr. Tina Marie deVries, Exec. VP of R&D (Age 58)
- Mr. James D. Schaub, Exec. VP & COO (Age 37)
- Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55)
When did Osmotica Pharmaceuticals IPO?
(OSMT) raised $58 million in an IPO on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO.
When did Osmotica Pharmaceuticals' lock-up period expire?
Osmotica Pharmaceuticals' lock-up period expired on Tuesday, April 16th. Osmotica Pharmaceuticals had issued 6,650,000 shares in its initial public offering on October 18th. The total size of the offering was $46,550,000 based on an initial share price of $7.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.
Who are Osmotica Pharmaceuticals' major shareholders?
Osmotica Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.89%), Broadfin Capital LLC (0.60%), Northern Trust Corp (0.18%), Morgan Stanley (0.10%), OppenheimerFunds Inc. (0.08%) and Hancock Whitney Corp (0.04%).
Which major investors are selling Osmotica Pharmaceuticals stock?
OSMT stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC and BlackRock Inc..
Which major investors are buying Osmotica Pharmaceuticals stock?
OSMT stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Hancock Whitney Corp, Northern Trust Corp, Acadian Asset Management LLC, SG Americas Securities LLC and OppenheimerFunds Inc..
How do I buy shares of Osmotica Pharmaceuticals?
Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Osmotica Pharmaceuticals' stock price today?
One share of OSMT stock can currently be purchased for approximately $2.60.
How big of a company is Osmotica Pharmaceuticals?
Osmotica Pharmaceuticals has a market capitalization of $133.95 million and generates $263.70 million in revenue each year. The company earns $-109,400,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe.
What is Osmotica Pharmaceuticals' official website?
How can I contact Osmotica Pharmaceuticals?
Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]
MarketBeat Community Rating for Osmotica Pharmaceuticals (NASDAQ OSMT)
MarketBeat's community ratings are surveys of what our community members think about Osmotica Pharmaceuticals and other stocks. Vote "Outperform" if you believe OSMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
